| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Asthma (BASKET)CD28CTLA4CD80CD86ICOSB7RP1Haut (Neoplasia Melanoma)IpilimumabTremelimumabNOD mouseRegulatory T cell| 1 | 2006 | CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma. | 
| + | - | nl | Allergy 61(1):15-26 (2006) Chen YQ |
| 2 | 1999 | The role of CTLA-4 in the regulation of T cell immune responses. | 
| + | - | nl | Immunol Cell Biol 77(1):1-10 (1999) |
| 3 | 1997 | The emerging role of CTLA-4 as an immune attenuator. |
| + | - | nl | Immunity 7(4):445-50 (1997) |
| 4 | 2000 | CD28, CTLA-4 and their ligands: who does what and to whom? |
| + | - | nl | Immunology 101(2):169-77 (2000) |
| 5 | 2007 | Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. |
| + | - | nl | Cancer 110(12):2614-27 (2007) |
| 6 | 2007 | Cytotoxic T-lymphocyte-associated antigen-4. |
| + | - | nl | Clin Cancer Res 13(18 Pt 1):5238-42 (2007) |
| 7 | 2008 | Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). |
| + | - | nl | Oncologist 13 Suppl 4(-):16-25 (2008) |
| 8 | 2008 | Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). |
| + | - | nl | Oncologist 13 Suppl 4(-):10-5 (2008) |
| 9 | 2008 | The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. |
| + | - | nl | Oncologist 13 Suppl 4(-):2-9 (2008) |
| 10 | 2008 | Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. | 
| + | - | nl | Ann N Y Acad Sci 1150(-):300-10 (2008) |
